
Predicting CLL Treatment with BCL-2 Dependence
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of abnormal lymphocytes. It is the most common form of

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of abnormal lymphocytes. It is the most common form of

Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof Alfredo Franco-Obregon & Dr Alex Tai Yee Kit, with N2CR

Nasopharyngeal carcinoma (NPC) is common in South China and parts of Southeast Asia. Despite treatment, 20-30% of patients relapse within five years and ultimately become resistant to standard platinum-based chemotherapy;

A study led by Dr Alan Prem Kumar, a member of N2CR, delves into how cancer arises from disruptions in cell cycle regulation, driven by mutations that fuel unchecked division

Gastric cancer (GC) has significant global mortality with high heterogeneity. A study of 226 GC samples from 121 patients integrated spatial transcriptomics and single-cell expression profiles, revealing extensive intratumour heterogeneity

The tumour microenvironment (TME) plays a pivotal role in cancer progression, metastasis, and therapeutic resistance. Comprised of diverse cells, extracellular matrix, and signaling molecules, the TME drives processes like epithelial-mesenchymal

Research led by N2CR member Dr. Cheok Chit Fang found that the tumour suppressor protein p53 protects DNA during replication by preventing the hyperactivation of PARP1 caused by oxidative stress.

Gold nanoparticles (NPs) are promising for cancer therapy due to their versatile properties. However, their interactions with cells vary, affecting reproducibility and application. To optimise this, Dr Andy Tay Kah

CIITA is the master regulator of MHC class-II immune genes that are important for defense mechanism against infections and cancer development. CIITA is controlled by three specific switches used in

Chemotherapy, although the first line of defense in cancer treatment, is indiscriminate and is damaging to the entire body, which, ironically, worsens a patient’s chances of getting better from cancer.